Antabio SAS raises €25 m in Series B financing
According to Antabio SAS, the financing will be used to support the clinical development of MEM-ANT3310 to proof-of-concept. MEM-ANT3310 is a next...
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...
Novo Nordisk Foundation in US$25m partnership with CARB-X
The Novo Nordisk Foundation is committing up to US$25m to support the early-stage development of drugs, vaccines and diagnostics to prevent,...
Spanish plant-based protein producer Heüra Foods closes Series B financing
Barcelona-based food tech start-up Heüra Foods Srl has cashed in €40m in a Series B financing round supported by Dutch Upfield Holdings BV, Unovis...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
Under the agreement set to close in Q3/2024, AstraZeneca will acquire Amolyt Pharma for US$800m upfront and potential milestone payments of US$250m....
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...